PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10037507-7 1999 Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA. Valproic Acid 60-63 glycogen synthase kinase 3 beta Homo sapiens 126-135 10037507-7 1999 Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA. Valproic Acid 60-63 glycogen synthase kinase 3 beta Homo sapiens 271-280 10037507-8 1999 Consistent with GSK-3beta inhibition, incubation of SH-SY5Y cells with VPA results in a significant time-dependent increase in both cytosolic and nuclear beta-catenin levels. Valproic Acid 71-74 glycogen synthase kinase 3 beta Homo sapiens 16-25 10037507-9 1999 GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents. Valproic Acid 168-171 glycogen synthase kinase 3 beta Homo sapiens 0-9 10037507-9 1999 GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents. Valproic Acid 168-171 glycogen synthase kinase 3 beta Homo sapiens 187-196